Browsing by Subject "Hematology"

Now showing 1 - 19 of 19
  • Thumbnail Image
    ItemOpen Access
    Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma
    (BLOOD, 2016-12-29) Xu-Monette, Zijun Y; Li, Ling; Byrd, John C; Jabbar, Kausar J; Manyam, Ganiraju C; de Winde, Charlotte Maria; van den Brand, Michiel; Tzankov, Alexandar; Visco, Carlo; Wang, Jing; Dybkaer, Karen; Chiu, April; Orazi, Attilio; Zu, Youli; Bhagat, Govind; Richards, Kristy L; Hsi, Eric D; Choi, William WL; Huh, Jooryung; Ponzoni, Maurilio; Ferreri, Andres JM; Moller, Michael B; Parsons, Ben M; Winter, Jane N; Wang, Michael; Hagemeister, Frederick B; Piris, Miguel A; van Krieken, J Han; Medeiros, L Jeffrey; Li, Yong; van Spriel, Annemiek B; Young, Ken H
  • Thumbnail Image
    ItemOpen Access
    Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.
    (Blood cancer journal, 2019-08-05) Clay-Gilmour, Alyssa I; Rishi, Abdul R; Goldin, Lynn R; Greenberg-Worisek, Alexandra J; Achenbach, Sara J; Rabe, Kari G; Maurer, Matthew J; Kay, Neil E; Shanafelt, Tait D; Call, Timothy G; Brice Weinberg, J; Camp, Nicola J; Cerhan, James R; Leis, Jose; Norman, Aaron; Murray, David L; Vincent Rajkumar, S; Caporaso, Neil E; Landgren, Ola; McMaster, Mary L; Slager, Susan L; Vachon, Celine M
    Chronic lymphocytic leukemia (CLL) and its precursor, monoclonal B-cell lymphocytosis (MBL), are heritable. Serumfree light-chain (sFLC) measures are a prognostic factor for CLL, but their role in susceptibility to CLL is not clear. We investigated differences between sFLC measurements in pre-treatment serum from five groups to inform the association of sFLC with familial and sporadic CLL: (1) familial CLL (n = 154), (2) sporadic CLL (n = 302), (3) familial MBL (n = 87), (4) unaffected first-degree relatives from CLL/MBL families (n = 263), and (5) reference population (n = 15,396). The percent of individuals having elevated monoclonal and polyclonal sFLCs was compared using age-stratified and age- and sex-adjusted logistic regression models. In age groups >50 years, monoclonal sFLC elevations were increased in sporadic and familial CLL cases compared to the reference population (p's < 0.05). However, there were no statistically significant differences in sFLC monoclonal or polyclonal elevations between familial and sporadic CLL cases (p's > 0.05). Unaffected relatives and MBL cases from CLL/MBL families, ages >60 years, showed elevated monoclonal sFLC, compared to the reference population (p's < 0.05). This is the first study to demonstrate monoclonal sFLC elevations in CLL cases compared to controls. Monoclonal sFLC levels may provide additional risk information in relatives of CLL probands.
  • Thumbnail Image
    ItemOpen Access
    Cord blood derived cell therapy product, DUOC-01, accelerates remyelination in a murine model of cuprizone induced demyelination
    (Cytotherapy, 2015-06) Saha, Arjun; Buntz, Susan; Patel, Sachit; Bentz, Marcia; Snyder, David; Ozamiz, April; Rusche, Benjamin; Gentry, Tracy; Glenn, Matsushima; Kurtzberg, Joanne; Balber, Andrew
  • Thumbnail Image
    ItemOpen Access
    Depression, quality of life, and medical resource utilization in sickle cell disease.
    (Blood advances, 2017-10-12) Adam, Soheir S; Flahiff, Charlene M; Kamble, Shital; Telen, Marilyn J; Reed, Shelby D; De Castro, Laura M
    Sickle cell disease (SCD) is a chronic, debilitating disorder. Chronically ill patients are at risk for depression, which can affect health-related quality of life (HRQoL), health care utilization, and cost. We performed an analytic epidemiologic prospective study to determine the prevalence of depression in adult patients with SCD and its association with HRQoL and medical resource utilization. Depression was measured by the Beck Depression Inventory and clinical history in adult SCD outpatients at a comprehensive SCD center. HRQoL was assessed using the SF36 form, and data were collected on medical resource utilization and corresponding cost. Neurocognitive functions were assessed using the CNS Vital Signs tool. Pain diaries were used to record daily pain. Out of 142 enrolled patients, 42 (35.2%) had depression. Depression was associated with worse physical and mental HRQoL scores (P < .0001 and P < .0001, respectively). Mean total inpatient costs ($25 000 vs $7487, P = .02) and total health care costs ($30 665 vs $13 016, P = .01) were significantly higher in patients with depression during the 12 months preceding diagnosis. Similarly, during the 6 months following diagnosis, mean total health care costs were significantly higher in depressed patients than in nondepressed patients ($13 766 vs $8670, P = .04). Depression is prevalent in adult patients with SCD and is associated with worse HRQoL and higher total health care costs. Efforts should focus on prevention, early diagnosis, and therapy for depression in SCD.
  • Thumbnail Image
    ItemOpen Access
    DUOC-01, A CANDIDATE CELL THERAPY PRODUCT DERIVED FROM BANKED CORD BLOOD, ACCELERATES BRAIN REMYELINATION IN NSG MICE FOLLOWING CUPRIZONE FEEDING
    (CYTOTHERAPY, 2014-04-01) Saha, A; Buntz, S; Patel, S; Matsushima, GK; Wollish, A; Kurtzberg, J; Balber, A
  • Thumbnail Image
    ItemOpen Access
    Eighth Annual International Umbilical Cord Blood Transplantation Symposium, San Francisco, California, June 3-5, 2010.
    (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011-02) Laughlin, Mary; Kurtzberg, Joanne; McMannis, John; Petz, Lawrence
  • Thumbnail Image
    ItemOpen Access
    End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.
    (Blood advances, 2019-12) Farrell, Ann T; Panepinto, Julie; Carroll, C Patrick; Darbari, Deepika S; Desai, Ankit A; King, Allison A; Adams, Robert J; Barber, Tabitha D; Brandow, Amanda M; DeBaun, Michael R; Donahue, Manus J; Gupta, Kalpna; Hankins, Jane S; Kameka, Michelle; Kirkham, Fenella J; Luksenburg, Harvey; Miller, Shirley; Oneal, Patricia Ann; Rees, David C; Setse, Rosanna; Sheehan, Vivien A; Strouse, John; Stucky, Cheryl L; Werner, Ellen M; Wood, John C; Zempsky, William T
    To address the global burden of sickle cell disease (SCD) and the need for novel therapies, the American Society of Hematology partnered with the US Food and Drug Administration to engage the work of 7 panels of clinicians, investigators, and patients to develop consensus recommendations for clinical trial end points. The panels conducted their work through literature reviews, assessment of available evidence, and expert judgment focusing on end points related to: patient-reported outcomes (PROs), pain (non-PROs), the brain, end-organ considerations, biomarkers, measurement of cure, and low-resource settings. This article presents the findings and recommendations of the PROs, pain, and brain panels, as well as relevant findings and recommendations from the biomarkers panel. The panels identify end points, where there were supporting data, to use in clinical trials of SCD. In addition, the panels discuss where further research is needed to support the development and validation of additional clinical trial end points.
  • Thumbnail Image
    ItemOpen Access
    Human cord blood derived CD14 cell therapy provides neuroprotection in aquired brain injury
    (Cytotherapy, 2015-06) Patel, Sachit; Saha, Arjun; Buntz, Susan; Bentz, Marcia; Scotland, Paula; Storms, Robert; Ramamurthy, Poorna; Kurtzberg, Joanne; Balber, Andrew
  • Thumbnail Image
    ItemOpen Access
    Increase the quality of banked cord blood units without limiting HLA diversity: how cord blood banks could face this dilemma
    (Transfusion, 2014-02) Magalon, Jeremy; Gamerre, Marc; Picard, Christophe; Chabannon, Christian
  • Thumbnail Image
    ItemOpen Access
    MYELOABLATIVE (MAC) AUTOLOGOUS STEM-CELL TRANSPLANTATION (AUTOSCT) FOLLOWED BY REDUCED INTENSITY (RIC) ALLOGENEIC STEM-CELL TRANSPLANTATION (ALLOSCT) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS (CAYA) WITH POOR RISK HODGKIN LYMPHOMA (HL): INDUCTION OF LONG-TERM GVHL EFFECT
    (PEDIATRIC BLOOD & CANCER, 2011-05-01) Satwani, P; Harrison, L; Bhatia, M; Bradley, MB; Garvin, JH; George, D; Martin, P; Kurtzberg, J; Schwartz, J; Baxter-Lowe, LA; Cairo, MS
  • Thumbnail Image
    ItemOpen Access
    Neural engraftment of a cord blood-derived cell product following intrathecal transplantation
    (Cytotherapy, 2015-06) Storms, Robert; Lew, Joanna; Liu, Congxiao; Gentry, Tracy; Ozamiz, April; Rusche, Benjamin; Balber, Andrew; Kurtzberg, Joanne
  • Thumbnail Image
    ItemOpen Access
  • Thumbnail Image
    ItemOpen Access
    Preclinical characterization of DUOC-01, a candidate cell therapy product derived from human banked umbilical cord blood intended for use in treatment of demyelinating diseases
    (Cytotherapy, 2014-04) Kurtzberg, J; Buntz, S; Gentry, T; Storms, R; Wenger, DA; Noldner, P; Zhou, J; Ozamiz, A; Rusche, B; Balber, A
  • Thumbnail Image
    ItemOpen Access
  • Thumbnail Image
    ItemOpen Access
    Survival following allogeneic transplant in patients with myelofibrosis.
    (Blood advances, 2020-05) Gowin, Krisstina; Ballen, Karen; Ahn, Kwang Woo; Hu, Zhen-Huan; Ali, Haris; Arcasoy, Murat O; Devlin, Rebecca; Coakley, Maria; Gerds, Aaron T; Green, Michael; Gupta, Vikas; Hobbs, Gabriela; Jain, Tania; Kandarpa, Malathi; Komrokji, Rami; Kuykendall, Andrew T; Luber, Kierstin; Masarova, Lucia; Michaelis, Laura C; Patches, Sarah; Pariser, Ashley C; Rampal, Raajit; Stein, Brady; Talpaz, Moshe; Verstovsek, Srdan; Wadleigh, Martha; Agrawal, Vaibhav; Aljurf, Mahmoud; Angel Diaz, Miguel; Avalos, Belinda R; Bacher, Ulrike; Bashey, Asad; Beitinjaneh, Amer M; Cerny, Jan; Chhabra, Saurabh; Copelan, Edward; Cutler, Corey S; DeFilipp, Zachariah; Gadalla, Shahinaz M; Ganguly, Siddhartha; Grunwald, Michael R; Hashmi, Shahrukh K; Kharfan-Dabaja, Mohamed A; Kindwall-Keller, Tamila; Kröger, Nicolaus; Lazarus, Hillard M; Liesveld, Jane L; Litzow, Mark R; Marks, David I; Nathan, Sunita; Nishihori, Taiga; Olsson, Richard F; Pawarode, Attaphol; Rowe, Jacob M; Savani, Bipin N; Savoie, Mary Lynn; Seo, Sachiko; Solh, Melhem; Tamari, Roni; Verdonck, Leo F; Yared, Jean A; Alyea, Edwin; Popat, Uday; Sobecks, Ronald; Scott, Bart L; Nakamura, Ryotaro; Mesa, Ruben; Saber, Wael
    Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.
  • Thumbnail Image
    ItemOpen Access
    THE NEW BD STEM CELL ENUMERATION METHOD BY FLOW CYTOMETRY SHOWS CONCORDANT RESULTS ACROSS FOUR STUDY SITES
    (INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2012-06-01) Omana-Zapata, Imelda; Segurado, Oscar; Kurtzberg, Joanne; Dornsife, Ronna; Preti, Robert; Chan, Wai-shun; Wallace, Paul K; Furlage, Rosemary; Tonn, Torsten; Bonig, Halvard
  • Thumbnail Image
    ItemOpen Access
    The use of hydroxyethyl starch (HES) as a substitute for dextran 40 in the thaw and washing of HPC, apheresis products
    (Cytotherapy, 2015-06) Zhu, Fenlu; Heidtke, Sarah M; Kurtzberg, Joanne; Hari, Parameswaran; Margolis, David A; Keever-Taylor, Carolyn
  • Thumbnail Image
    ItemOpen Access
    Tissue distribution of a cord blood-derived cell product following intrathecal transplantation
    (Cytotherapy, 2014-04) Storms, R; Liu, C; Gentry, T; Zhou, J; Ozamiz, A; Rusche, B; Balber, A; Kurtzberg, J
  • Thumbnail Image
    ItemOpen Access
    What's up with 2 cord transplantation?
    (Blood, 2011-03) Kurtzberg, Joanne
    Transplantation of 2 cord blood units to a single patient has been enthusiastically adopted as a strategy to increase access to unrelated donor cord blood transplantation (UCBT) for larger pediatric and adult patients. With this strategy, 1 cord blood unit ultimately dominates and confers durable engraftment, but prospective identification of the engrafting unit has not been possible.